Ultragenyx Pharma (RARE) Misses Q3 EPS by 11c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. EBAY
6. TENB
7. CMG
8. KLAC
9. BIIB
10. ETSY

Go back to Ultragenyx Pharma (RARE) Misses Q3 EPS by 11c

Ultragenyx Reports Third Quarter 2016 Financial Results and Corporate Update

November 7, 2016 4:05 PM EST

NOVATO, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the quarter ended September 30, 2016.

Based on recent discussions with the FDA, we now plan to file for US approval of KRN23 in the second half of 2017, said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. We expect continued clinical and regulatory progress across all of our programs, including filings for rhGUS and... More